Your browser is no longer supported. Please, upgrade your browser.
Settings
TCDA Tricida, Inc. daily Stock Chart
TCDA [NASD]
Tricida, Inc.
Index- P/E- EPS (ttm)-2.43 Insider Own2.70% Shs Outstand42.68M Perf Week-4.12%
Market Cap1.33B Forward P/E- EPS next Y-3.34 Insider Trans- Shs Float40.88M Perf Month22.44%
Income-102.80M PEG- EPS next Q-0.80 Inst Own92.90% Short Float3.26% Perf Quarter45.81%
Sales- P/S- EPS this Y-136.10% Inst Trans-0.61% Short Ratio3.57 Perf Half Y2.43%
Book/sh4.25 P/B7.33 EPS next Y9.60% ROA-62.70% Target Price50.00 Perf Year-
Cash/sh5.65 P/C5.52 EPS next 5Y- ROE-237.60% 52W Range19.43 - 40.83 Perf YTD32.15%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-23.68% Beta-
Dividend %- Quick Ratio16.50 Sales past 5Y- Gross Margin- 52W Low60.37% ATR2.35
Employees76 Current Ratio16.50 Sales Q/Q- Oper. Margin- RSI (14)50.51 Volatility6.04% 9.44%
OptionableNo Debt/Eq0.00 EPS Q/Q40.80% Profit Margin- Rel Volume0.73 Prev Close31.51
ShortableYes LT Debt/Eq0.20 EarningsMar 28 BMO Payout- Avg Volume373.09K Price31.16
Recom2.50 SMA20-3.69% SMA5015.69% SMA20012.71% Volume273,215 Change-1.11%
Jul-23-18Initiated JP Morgan Neutral $34
Jul-23-18Initiated Goldman Neutral $32
Apr-08-19 05:03PM  Here's What Drove Tricida 67% Higher in March Motley Fool
04:05PM  Tricida Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Apr-04-19 09:57AM  The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy Zacks
Apr-03-19 08:07PM  Tricida Announces Pricing of Public Offering of Common Stock Business Wire
09:16AM  Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy Zacks
Apr-01-19 04:39PM  Why MAG Silver, comScore, and Tricida Slumped Today Motley Fool -8.52%
04:36PM  Tricida Announces Proposed Public Offering of Common Stock Business Wire
05:34AM  Will Tricida Continue to Surge Higher? Zacks
Mar-28-19 04:37PM  Tricida Surges on Positive Results of Chronic Kidney Disease Treatment TheStreet.com +57.04%
03:57PM  Here's Why Tricida's Soaring Today Motley Fool
11:33AM  Tricida Inc (TCDA) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:15AM  Tricida Announces Positive Results From Long-Term Clinical Trial of TRC101 in Patients With CKD and Metabolic Acidosis Business Wire
07:07AM  Tricida Announces $200 Million Debt Facility With Hercules Capital Business Wire
07:00AM  Tricida Announces Fourth Quarter and Full-Year 2018 Financial Results Business Wire
06:00AM  Tricida Inc to Host Earnings Call ACCESSWIRE
Mar-27-19 04:44PM  Tricida to Report Long-Term Clinical Trial Results for TRC101 in CKD Patients with Metabolic Acidosis and Host Conference Call and Webcast on Thursday, March 28, 2019 Business Wire
Mar-11-19 08:30AM  Tricida Announces Publication of Positive TRC101 Pivotal Trial Results in The Lancet Business Wire
Mar-07-19 10:00AM  Tricida to Report Fourth Quarter and Full-Year 2018 Financial Results and Host Conference Call and Webcast on Thursday, March 28, 2019 Business Wire
Feb-27-19 10:00AM  Tricida to Present at the Cowen and Company 39th Annual Health Care Conference Business Wire
Jan-17-19 08:30AM  Tricida Announces Hiring of Susannah Cantrell, Ph.D., as Chief Commercial Officer Business Wire -5.44%
Jan-02-19 02:00PM  Tricida to Present at the 37th Annual J. P. Morgan Healthcare Conference Business Wire
Dec-20-18 10:35PM  Tricida, Inc. (TCDA): Hedge Fund Sentiment Unchanged Insider Monkey -6.26%
Nov-08-18 04:05PM  Tricida Announces Third Quarter 2018 Financial Results Business Wire
Nov-01-18 10:00AM  Tricida to Report Third Quarter Financial Results and Host Conference Call and Webcast on Thursday, November 8, 2018 Business Wire
Oct-04-18 04:26PM  Tricida Announces Presentation of TRCA-301 Pivotal Trial Results at the American Society of Nephrology Kidney Week Meeting in San Diego, October 23 - 28 Business Wire
Aug-08-18 04:05PM  Tricida Announces Second Quarter 2018 Financial Results and Provides Update on Key Initiatives Business Wire
03:00PM  Tricida Inc to Host Earnings Call ACCESSWIRE
Aug-01-18 08:30AM  Tricida Announces Hiring of Dawn Parsell as Senior Vice President of Clinical Development Business Wire
Jul-31-18 05:43PM  Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Wednesday, August 8, 2018 Business Wire
Jul-23-18 04:27PM  Tricida Post-IPO Run-up Makes Goldman Wary Benzinga
Jul-18-18 08:01PM  [$$] Biotech IPO Boom Comes With Side Effects The Wall Street Journal
12:26PM  [$$] Biotech IPO Boom Comes With Side Effects The Wall Street Journal
Jul-02-18 04:05PM  Tricida Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
07:30AM  [$$] Biotech Companies Continue IPO Hot Streak, But For How Long? The Wall Street Journal
Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.